Best Biotechnology Engineer Carlsbad Near Me

4worldlovers: Predictive Biology brings together genetics, stem cell biology, organoids and single cell technologies to characterize the molecular basis of disease phenotypes and drug response.


We use our in vitro genetics platform to elucidate molecular mechanisms of action and to find and validate novel drug targets.

Cytotoxic Edema: a genetic screen for genes that modify cell swelling in astrocytes.

Psychiatric Genetics: an eQTL screen across cerebral organoids for mechanistic studies in autism and other psychiatric and neurodevelopmental disorders.

Preclinical studies usually test compound action in a small number of cell lines and animal models. Response in genetically diverse backgrounds is often considered only in clinical studies, where there is limited statistical power and no opportunity to modify the molecule. We believe that drug action across genetic diversity should be evaluated in preclinical studies when the molecule has druglike properties but remains available for chemical modification. At this stage, there is little if any data from in vivo studies.

Impact on Discovery: In vitro genetic screens can be used to identify causal mediators of drug response, and genetically validated targets can double the likelihood of a successful drug discovery program.

Impact on Prioritization: Chemically related preclinical compounds often exhibit different pharmacological properties. A better understanding of the mechanism of action would help prioritize them for clinical studies.

It is widely accepted that genetics plays a major role in susceptibility to toxicants but how genetics shapes toxic response is poorly understood. For environmental health science, finding the genes that modulate susceptibility will drive mechanistic understanding of toxicity, which in turn will drive development of more predictive toxicity assays. For public safety, genetic stratification of susceptibility can aid exposure limit setting by regulatory bodies.

For drug discovery, where safety issues account for half of drug failures in clinical trials, identifying genes and pathways that modulate adverse drug response can lead to better engineered molecules that reduce safety risk. For preventive medicine, identifying those at greater risk from toxicant exposure can improve allocation of limited healthcare resources.

Current toxicology research projects include an SBIR funded project to use cerebral organoids to identify modifiers of developmental neurotoxicants, and an SBIR funded project to develop an improved aneuploidy assay using single cell RNAseq.

We are located in Carlsbad CA,30 miles north of San Diego and 20 miles north of La Jolla.

4worldlovers:
Sample collection devices for whole blood, saliva, sweat, tears, urine, environmental samples, plant, soil, water, food, and more

Integrated devices for use in the field: military, agricultural, veterinary, or medical

Modern rapid point-of-use testing requires high-performance sample collection devices, cartridges, and reader systems. DCN Dx ensures they're designed for maximum usability and performance, no matter the application.

3D design, modeling, and DFM for motion control, fluidics, and instrument systems, including injection molding, instrument housings, thermal systems, and more

Analog and digital circuit design (low- and high-complexity). Includes schematic capture and PCB layout

4worldlovers: Our goal is to drive innovation that reduces the cost of biopharma manufacturing and as an educational institution to ensure the training of life sciences professionals for the newest biopharmaceutical manufacturing and related technologies.

Life Science companies are major drivers of innovation and the economy in California and the entire west coast of the US. California’s indirect employment due to life science companies results in over 900,000 jobs, with 311,226 direct life science jobs having an average wage over $100,000 annually (CLSA 2019 report.) We recognize that more than forty percent of upcoming therapeutics in their respective R&D pipelines are biopharmaceuticals. The life science industry has a critical shortage of trained process development and biomanufacturing personnel, ranging in some areas as much as 40 to 50%.

Open Biopharma operates the FutureFacility designed and constructed with CRB. Open Biopharma uses a ballroom design to create a truly dynamic space, the Sandbox. The Sandbox holds a variety of the latest equipment and technology platforms; including single use, continuous, integrated, and automation from different vendors across the industry. The Sandbox concept allows biopharmaceutical companies, vendors, and regulators to evaluate the impact of these new technologies on the biopharmaceutical processes and facilitate the adaptation of these progressive technologies into industry best practices. To complement the Sandbox concept our additional focus is enhancement of industry through current best practices and future-facing training which helps drive innovation and regional development as well.

Our campus is the first of its kind on the west coast.

Our future biopharma manufacturing facility is located in Carlsbad, CA – strategically placed in the heart of the Southern California biotech cluster and within a two hour plane ride from the Bay Area, Seattle, Denver and other prominent BioPharma clusters. San Diego represents the fastest growing cluster within the BioPharma industry.

4worldlovers:
Millipore CTDMO Services delivers expertise and flexible solutions for viral vector development and manufacturing to advance cell and gene therapies from preclinical through commercial production.


Our proficiency with adeno-associated virus (AAV), lentivirus, adenovirus, and other vectors helps streamline the development and manufacturing of cell and gene therapies. From early preclinical through clinical and commercial manufacturing, we offer the comprehensive resources, capabilities, and know-how to advance current and future cell and gene therapies to market.


Our track record includes successful regulatory inspections by the U.S. Food & Drug Administration (FDA), the European Medicines Agency (EMA), Health Canada, the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan, the Australian Therapeutic Goods Administration (TGA), and the Brazilian Health Regulatory Agency (ANVISA).


Our viral vector experts work with our clients to identify and evaluate improvements to current processes in order to streamline therapeutic production, address risk, and accelerate cell and gene therapies to the clinic. Through our Manufacturability Assessment, we:

4worldlovers:
Our breakthrough High Definition PCR (HDPCR) multiplexing platform has the power to transform diagnostics, now and in the future—without sacrificing quality. Access actionable biomarkers in your lab with a simple, fast, and affordable solution.

Enhance the capacity and the multiplexing capabilities of your existing PCR 4 to 10 times